By Catherine Eckford (European Pharmaceutical Review)2024-09-27T16:21:58
The “landmark” approval represents the first new class of medicine in several decades for treating schizophrenia.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-09-19T15:46:00
Sponsored by ACCI, By European Pharmaceutical Review
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
2025-10-22T14:00:00
Sponsored by Bruker
Site powered by Webvision Cloud